Report Thumbnail
Product Code LP09152144758EY
Published Date 2023/6/27
LP Information
English112 PagesGlobal

Global Benzodiazepine Receptor Agonists Market Growth 2023-2029 ‐ Pharmaceutical_LifeSciense Market


Report Thumbnail
Product Code LP09152144758EY◆The Jun 2025 edition is also likely available. We will check with the publisher immediately.
Published Date 2023/6/27
LP Information
English 112 PagesGlobal

Global Benzodiazepine Receptor Agonists Market Growth 2023-2029 ‐ Pharmaceutical_LifeSciense Market


Abstract

Summary

The global Benzodiazepine Receptor Agonists market size is projected to grow from US$ 1007.6 million in 2022 to US$ 1725.5 million in 2029; it is expected to grow at a CAGR of 8.0% from 2023 to 2029.
The market view for benzodiazepine receptor agonists has shown steady growth due to the high prevalence of conditions such as anxiety disorders, insomnia, and other indications that these medications are used to treat. Factors contributing to the market growth include increasing awareness and diagnosis of mental health disorders, growing geriatric population, and the need for effective treatments for anxiety-related conditions.
Benzodiazepine receptor agonists, also known as benzodiazepines or BZDs, are a class of medications that act on the benzodiazepine receptors in the brain. These receptors are part of the gamma-aminobutyric acid (GABA) neurotransmitter system, which plays a crucial role in regulating neuronal activity and promoting relaxation and sedation.
LPI (LP Information)' newest research report, the “Benzodiazepine Receptor Agonists Industry Forecast” looks at past sales and reviews total world Benzodiazepine Receptor Agonists sales in 2022, providing a comprehensive analysis by region and market sector of projected Benzodiazepine Receptor Agonists sales for 2023 through 2029. With Benzodiazepine Receptor Agonists sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Benzodiazepine Receptor Agonists industry.
This Insight Report provides a comprehensive analysis of the global Benzodiazepine Receptor Agonists landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Benzodiazepine Receptor Agonists portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Benzodiazepine Receptor Agonists market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Benzodiazepine Receptor Agonists and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Benzodiazepine Receptor Agonists.
This report presents a comprehensive overview, market shares, and growth opportunities of Benzodiazepine Receptor Agonists market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Non-benzodiazepines
Benzodiazepines
Segmentation by application
Hospital
Clinic
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Teva Pharmaceuticals
Torrent Pharma
Roche
Akorn
Apotex
Fresenius Kabi
Hikma
Mylan
Par Pharmaceuticals
Sandoz
Sun Pharma
WG Critical Care
Athenex
Chenxin Pharmaceutical
Huatai Chenguang Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Benzodiazepine Receptor Agonists market?
What factors are driving Benzodiazepine Receptor Agonists market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Benzodiazepine Receptor Agonists market opportunities vary by end market size?
How does Benzodiazepine Receptor Agonists break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

Table of Contents

  • 1 Scope of the Report

    • 1.1 Market Introduction
    • 1.2 Years Considered
    • 1.3 Research Objectives
    • 1.4 Market Research Methodology
    • 1.5 Research Process and Data Source
    • 1.6 Economic Indicators
    • 1.7 Currency Considered
    • 1.8 Market Estimation Caveats

  • 2 Executive Summary

    • 2.1 World Market Overview
      • 2.1.1 Global Benzodiazepine Receptor Agonists Annual Sales 2018-2029
      • 2.1.2 World Current & Future Analysis for Benzodiazepine Receptor Agonists by Geographic Region, 2018, 2022 & 2029
      • 2.1.3 World Current & Future Analysis for Benzodiazepine Receptor Agonists by Country/Region, 2018, 2022 & 2029
    • 2.2 Benzodiazepine Receptor Agonists Segment by Type
      • 2.2.1 Non-benzodiazepines
      • 2.2.2 Benzodiazepines
    • 2.3 Benzodiazepine Receptor Agonists Sales by Type
      • 2.3.1 Global Benzodiazepine Receptor Agonists Sales Market Share by Type (2018-2023)
      • 2.3.2 Global Benzodiazepine Receptor Agonists Revenue and Market Share by Type (2018-2023)
      • 2.3.3 Global Benzodiazepine Receptor Agonists Sale Price by Type (2018-2023)
    • 2.4 Benzodiazepine Receptor Agonists Segment by Application
      • 2.4.1 Hospital
      • 2.4.2 Clinic
      • 2.4.3 Other
    • 2.5 Benzodiazepine Receptor Agonists Sales by Application
      • 2.5.1 Global Benzodiazepine Receptor Agonists Sale Market Share by Application (2018-2023)
      • 2.5.2 Global Benzodiazepine Receptor Agonists Revenue and Market Share by Application (2018-2023)
      • 2.5.3 Global Benzodiazepine Receptor Agonists Sale Price by Application (2018-2023)

  • 3 Global Benzodiazepine Receptor Agonists by Company

    • 3.1 Global Benzodiazepine Receptor Agonists Breakdown Data by Company
      • 3.1.1 Global Benzodiazepine Receptor Agonists Annual Sales by Company (2018-2023)
      • 3.1.2 Global Benzodiazepine Receptor Agonists Sales Market Share by Company (2018-2023)
    • 3.2 Global Benzodiazepine Receptor Agonists Annual Revenue by Company (2018-2023)
      • 3.2.1 Global Benzodiazepine Receptor Agonists Revenue by Company (2018-2023)
      • 3.2.2 Global Benzodiazepine Receptor Agonists Revenue Market Share by Company (2018-2023)
    • 3.3 Global Benzodiazepine Receptor Agonists Sale Price by Company
    • 3.4 Key Manufacturers Benzodiazepine Receptor Agonists Producing Area Distribution, Sales Area, Product Type
      • 3.4.1 Key Manufacturers Benzodiazepine Receptor Agonists Product Location Distribution
      • 3.4.2 Players Benzodiazepine Receptor Agonists Products Offered
    • 3.5 Market Concentration Rate Analysis
      • 3.5.1 Competition Landscape Analysis
      • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
    • 3.6 New Products and Potential Entrants
    • 3.7 Mergers & Acquisitions, Expansion

  • 4 World Historic Review for Benzodiazepine Receptor Agonists by Geographic Region

    • 4.1 World Historic Benzodiazepine Receptor Agonists Market Size by Geographic Region (2018-2023)
      • 4.1.1 Global Benzodiazepine Receptor Agonists Annual Sales by Geographic Region (2018-2023)
      • 4.1.2 Global Benzodiazepine Receptor Agonists Annual Revenue by Geographic Region (2018-2023)
    • 4.2 World Historic Benzodiazepine Receptor Agonists Market Size by Country/Region (2018-2023)
      • 4.2.1 Global Benzodiazepine Receptor Agonists Annual Sales by Country/Region (2018-2023)
      • 4.2.2 Global Benzodiazepine Receptor Agonists Annual Revenue by Country/Region (2018-2023)
    • 4.3 Americas Benzodiazepine Receptor Agonists Sales Growth
    • 4.4 APAC Benzodiazepine Receptor Agonists Sales Growth
    • 4.5 Europe Benzodiazepine Receptor Agonists Sales Growth
    • 4.6 Middle East & Africa Benzodiazepine Receptor Agonists Sales Growth

  • 5 Americas

    • 5.1 Americas Benzodiazepine Receptor Agonists Sales by Country
      • 5.1.1 Americas Benzodiazepine Receptor Agonists Sales by Country (2018-2023)
      • 5.1.2 Americas Benzodiazepine Receptor Agonists Revenue by Country (2018-2023)
    • 5.2 Americas Benzodiazepine Receptor Agonists Sales by Type
    • 5.3 Americas Benzodiazepine Receptor Agonists Sales by Application
    • 5.4 United States
    • 5.5 Canada
    • 5.6 Mexico
    • 5.7 Brazil

  • 6 APAC

    • 6.1 APAC Benzodiazepine Receptor Agonists Sales by Region
      • 6.1.1 APAC Benzodiazepine Receptor Agonists Sales by Region (2018-2023)
      • 6.1.2 APAC Benzodiazepine Receptor Agonists Revenue by Region (2018-2023)
    • 6.2 APAC Benzodiazepine Receptor Agonists Sales by Type
    • 6.3 APAC Benzodiazepine Receptor Agonists Sales by Application
    • 6.4 China
    • 6.5 Japan
    • 6.6 South Korea
    • 6.7 Southeast Asia
    • 6.8 India
    • 6.9 Australia
    • 6.10 China Taiwan

  • 7 Europe

    • 7.1 Europe Benzodiazepine Receptor Agonists by Country
      • 7.1.1 Europe Benzodiazepine Receptor Agonists Sales by Country (2018-2023)
      • 7.1.2 Europe Benzodiazepine Receptor Agonists Revenue by Country (2018-2023)
    • 7.2 Europe Benzodiazepine Receptor Agonists Sales by Type
    • 7.3 Europe Benzodiazepine Receptor Agonists Sales by Application
    • 7.4 Germany
    • 7.5 France
    • 7.6 UK
    • 7.7 Italy
    • 7.8 Russia

  • 8 Middle East & Africa

    • 8.1 Middle East & Africa Benzodiazepine Receptor Agonists by Country
      • 8.1.1 Middle East & Africa Benzodiazepine Receptor Agonists Sales by Country (2018-2023)
      • 8.1.2 Middle East & Africa Benzodiazepine Receptor Agonists Revenue by Country (2018-2023)
    • 8.2 Middle East & Africa Benzodiazepine Receptor Agonists Sales by Type
    • 8.3 Middle East & Africa Benzodiazepine Receptor Agonists Sales by Application
    • 8.4 Egypt
    • 8.5 South Africa
    • 8.6 Israel
    • 8.7 Turkey
    • 8.8 GCC Countries

  • 9 Market Drivers, Challenges and Trends

    • 9.1 Market Drivers & Growth Opportunities
    • 9.2 Market Challenges & Risks
    • 9.3 Industry Trends

  • 10 Manufacturing Cost Structure Analysis

    • 10.1 Raw Material and Suppliers
    • 10.2 Manufacturing Cost Structure Analysis of Benzodiazepine Receptor Agonists
    • 10.3 Manufacturing Process Analysis of Benzodiazepine Receptor Agonists
    • 10.4 Industry Chain Structure of Benzodiazepine Receptor Agonists

  • 11 Marketing, Distributors and Customer

    • 11.1 Sales Channel
      • 11.1.1 Direct Channels
      • 11.1.2 Indirect Channels
    • 11.2 Benzodiazepine Receptor Agonists Distributors
    • 11.3 Benzodiazepine Receptor Agonists Customer

  • 12 World Forecast Review for Benzodiazepine Receptor Agonists by Geographic Region

    • 12.1 Global Benzodiazepine Receptor Agonists Market Size Forecast by Region
      • 12.1.1 Global Benzodiazepine Receptor Agonists Forecast by Region (2024-2029)
      • 12.1.2 Global Benzodiazepine Receptor Agonists Annual Revenue Forecast by Region (2024-2029)
    • 12.2 Americas Forecast by Country
    • 12.3 APAC Forecast by Region
    • 12.4 Europe Forecast by Country
    • 12.5 Middle East & Africa Forecast by Country
    • 12.6 Global Benzodiazepine Receptor Agonists Forecast by Type
    • 12.7 Global Benzodiazepine Receptor Agonists Forecast by Application

  • 13 Key Players Analysis

    • 13.1 Pfizer
      • 13.1.1 Pfizer Company Information
      • 13.1.2 Pfizer Benzodiazepine Receptor Agonists Product Portfolios and Specifications
      • 13.1.3 Pfizer Benzodiazepine Receptor Agonists Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.1.4 Pfizer Main Business Overview
      • 13.1.5 Pfizer Latest Developments
    • 13.2 Teva Pharmaceuticals
      • 13.2.1 Teva Pharmaceuticals Company Information
      • 13.2.2 Teva Pharmaceuticals Benzodiazepine Receptor Agonists Product Portfolios and Specifications
      • 13.2.3 Teva Pharmaceuticals Benzodiazepine Receptor Agonists Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.2.4 Teva Pharmaceuticals Main Business Overview
      • 13.2.5 Teva Pharmaceuticals Latest Developments
    • 13.3 Torrent Pharma
      • 13.3.1 Torrent Pharma Company Information
      • 13.3.2 Torrent Pharma Benzodiazepine Receptor Agonists Product Portfolios and Specifications
      • 13.3.3 Torrent Pharma Benzodiazepine Receptor Agonists Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.3.4 Torrent Pharma Main Business Overview
      • 13.3.5 Torrent Pharma Latest Developments
    • 13.4 Roche
      • 13.4.1 Roche Company Information
      • 13.4.2 Roche Benzodiazepine Receptor Agonists Product Portfolios and Specifications
      • 13.4.3 Roche Benzodiazepine Receptor Agonists Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.4.4 Roche Main Business Overview
      • 13.4.5 Roche Latest Developments
    • 13.5 Akorn
      • 13.5.1 Akorn Company Information
      • 13.5.2 Akorn Benzodiazepine Receptor Agonists Product Portfolios and Specifications
      • 13.5.3 Akorn Benzodiazepine Receptor Agonists Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.5.4 Akorn Main Business Overview
      • 13.5.5 Akorn Latest Developments
    • 13.6 Apotex
      • 13.6.1 Apotex Company Information
      • 13.6.2 Apotex Benzodiazepine Receptor Agonists Product Portfolios and Specifications
      • 13.6.3 Apotex Benzodiazepine Receptor Agonists Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.6.4 Apotex Main Business Overview
      • 13.6.5 Apotex Latest Developments
    • 13.7 Fresenius Kabi
      • 13.7.1 Fresenius Kabi Company Information
      • 13.7.2 Fresenius Kabi Benzodiazepine Receptor Agonists Product Portfolios and Specifications
      • 13.7.3 Fresenius Kabi Benzodiazepine Receptor Agonists Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.7.4 Fresenius Kabi Main Business Overview
      • 13.7.5 Fresenius Kabi Latest Developments
    • 13.8 Hikma
      • 13.8.1 Hikma Company Information
      • 13.8.2 Hikma Benzodiazepine Receptor Agonists Product Portfolios and Specifications
      • 13.8.3 Hikma Benzodiazepine Receptor Agonists Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.8.4 Hikma Main Business Overview
      • 13.8.5 Hikma Latest Developments
    • 13.9 Mylan
      • 13.9.1 Mylan Company Information
      • 13.9.2 Mylan Benzodiazepine Receptor Agonists Product Portfolios and Specifications
      • 13.9.3 Mylan Benzodiazepine Receptor Agonists Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.9.4 Mylan Main Business Overview
      • 13.9.5 Mylan Latest Developments
    • 13.10 Par Pharmaceuticals
      • 13.10.1 Par Pharmaceuticals Company Information
      • 13.10.2 Par Pharmaceuticals Benzodiazepine Receptor Agonists Product Portfolios and Specifications
      • 13.10.3 Par Pharmaceuticals Benzodiazepine Receptor Agonists Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.10.4 Par Pharmaceuticals Main Business Overview
      • 13.10.5 Par Pharmaceuticals Latest Developments
    • 13.11 Sandoz
      • 13.11.1 Sandoz Company Information
      • 13.11.2 Sandoz Benzodiazepine Receptor Agonists Product Portfolios and Specifications
      • 13.11.3 Sandoz Benzodiazepine Receptor Agonists Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.11.4 Sandoz Main Business Overview
      • 13.11.5 Sandoz Latest Developments
    • 13.12 Sun Pharma
      • 13.12.1 Sun Pharma Company Information
      • 13.12.2 Sun Pharma Benzodiazepine Receptor Agonists Product Portfolios and Specifications
      • 13.12.3 Sun Pharma Benzodiazepine Receptor Agonists Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.12.4 Sun Pharma Main Business Overview
      • 13.12.5 Sun Pharma Latest Developments
    • 13.13 WG Critical Care
      • 13.13.1 WG Critical Care Company Information
      • 13.13.2 WG Critical Care Benzodiazepine Receptor Agonists Product Portfolios and Specifications
      • 13.13.3 WG Critical Care Benzodiazepine Receptor Agonists Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.13.4 WG Critical Care Main Business Overview
      • 13.13.5 WG Critical Care Latest Developments
    • 13.14 Athenex
      • 13.14.1 Athenex Company Information
      • 13.14.2 Athenex Benzodiazepine Receptor Agonists Product Portfolios and Specifications
      • 13.14.3 Athenex Benzodiazepine Receptor Agonists Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.14.4 Athenex Main Business Overview
      • 13.14.5 Athenex Latest Developments
    • 13.15 Chenxin Pharmaceutical
      • 13.15.1 Chenxin Pharmaceutical Company Information
      • 13.15.2 Chenxin Pharmaceutical Benzodiazepine Receptor Agonists Product Portfolios and Specifications
      • 13.15.3 Chenxin Pharmaceutical Benzodiazepine Receptor Agonists Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.15.4 Chenxin Pharmaceutical Main Business Overview
      • 13.15.5 Chenxin Pharmaceutical Latest Developments
    • 13.16 Huatai Chenguang Pharmaceutical
      • 13.16.1 Huatai Chenguang Pharmaceutical Company Information
      • 13.16.2 Huatai Chenguang Pharmaceutical Benzodiazepine Receptor Agonists Product Portfolios and Specifications
      • 13.16.3 Huatai Chenguang Pharmaceutical Benzodiazepine Receptor Agonists Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.16.4 Huatai Chenguang Pharmaceutical Main Business Overview
      • 13.16.5 Huatai Chenguang Pharmaceutical Latest Developments

  • 14 Research Findings and Conclusion

USD 3,660 or Partial Purchase
*Prices are subject to change by the publisher.
© 2026 ShareFair Inc.